Skip to Content
Merck
All Photos(1)

Documents

E-068

Supelco

Everolimus solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C53H83NO14
CAS Number:
159351-69-6
Molecular Weight:
958.22
MDL number:
MFCD00929329
UNSPSC Code:
41116107
PubChem Substance ID:
329798983
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

(Snap-N-Spike®)

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

shipped in

dry ice

storage temp.

−70°C

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI key

HKVAMNSJSFKALM-GKUWKFKPSA-N

Gene Information

human ... FKBP1A(2280)

Related Categories

General description

Everolimus, sold under trade names including Zortress®, Certican, and Afinitor®, is an immunosuppressant drug used to prevent rejection of organ transplants and to treat renal cell cancer and other tumors. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of everolimus in patient whole blood samples by LC-MS/MS.

Application


  • Everolimus as a therapy for hepatoblastoma: Research demonstrates that Everolimus can induce autophagy-dependent ferroptosis in hepatoblastoma cells, highlighting its potential as a therapeutic agent in oncology research. This study provides insight into the mechanisms by which Everolimus can be utilized to target cancer cells through cell death pathways (Huang et al., 2024).

  • Understanding oral mucosal injuries from mTOR inhibitors: A new hypothesis posits that oral mucosal injuries associated with mTOR inhibitors like Everolimus result from disruptions in cellular stress and apoptotic pathways. This study underscores the importance of understanding side effects in the context of targeted therapy for conditions such as cancers and immunosuppression (Sonis and Villa, 2023).

  • Micellar formulation of Everolimus for neurological disorders: A stable micellar formulation of Everolimus (RAD001) has been developed for intracerebroventricular delivery, aimed at treating Alzheimer′s Disease and other neurological disorders. This formulation allows for direct brain administration, potentially enhancing the drug′s efficacy and safety profile (Gianessi et al., 2023).

  • Pharmacokinetics in epilepsy treatment: The population pharmacokinetics of Everolimus were studied in patients with seizures associated with focal cortical dysplasia. This research aids in understanding the drug′s behavior in a specific neurological context, providing a foundation for dosing adjustments and therapeutic monitoring (Park et al., 2023).

Legal Information

Afinitor is a registered trademark of Novartis AG
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zortress is a registered trademark of Novartis AG

Pictograms

FlameExclamation mark
GHS02,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

35.6 °F - closed cup

Flash Point(C)

2.0 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matteo Santoni et al.
Biochimica et biophysica acta, 1845(2), 221-231 (2014-02-01)
The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Treatment of metastatic renal cell carcinoma (mRCC) has improved significantly with the advent of agents targeting the mTOR pathway, such as temsirolimus and everolimus. Unfortunately, a
Michael Cardamone et al.
The Journal of pediatrics, 164(5), 1195-1200 (2014-02-13)
To evaluate the efficacy and side effects of oral mammalian target of rapamycin (mTOR) inhibitors in children and adolescents with tuberous sclerosis complex (TSC) and intractable epilepsy or subependymal giant cell astrocytoma (SEGA). Single-center series of 13 children and adolescents
Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities.
Piguet AC, Majumder S, Maheshwari U, et al.
Clinical Science, 126(11), 775-784 (2014)
Elisavet Paplomata et al.
Breast cancer research and treatment, 140(3), 453-462 (2013-08-03)
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR), which has been approved in combination with exemestane for hormone receptor-positive (HR) breast cancer after failure of treatment with non-steroidal aromatase inhibitors. Everolimus is generally very well
Eleonora Teplinsky et al.
Breast cancer research and treatment, 141(2), 167-172 (2013-09-05)
Hepatitis B reactivation can occur with cytotoxic chemotherapy in patients with hepatitis B and cancer. Reactivation can occur in a patient with chronic hepatitis, an inactive carrier, or one with resolved hepatitis. Clinical presentation may range from subclinical elevation of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service